Literature DB >> 2846494

Effect of inhibition of 5-lipoxygenase metabolism of arachidonic acid on response to endotoxemia in sheep.

J W Coggeshall1, B W Christman, P L Lefferts, W E Serafin, I A Blair, M J Butterfield, J R Snapper.   

Abstract

We studied the effects of a 5-lipoxygenase inhibitor, L-651,192, on the pulmonary dysfunction caused by endotoxemia in chronically instrumented unanesthetized sheep. The efficacy and selectivity of L-651,392 were tested by measuring in vivo production of leukotriene B4 (LTB4) and cyclooxygenase products of arachidonic acid after endotoxemia before and after pretreatment with L-651,392 and ex vivo from granulocytes and whole blood stimulated with calcium ionophore from sheep before and 24 h after pretreatment with L-651,392. A novel assay for LTB4 by high-performance liquid chromatography/gas chromatography/mass spectrometry techniques was developed as a measure of 5-lipoxygenase metabolism of arachidonic acid. L-651,392 proved to be an effective in vivo 5-lipoxygenase inhibitor in sheep. L-651,392 blocked the increase in LTB4 observed in lung lymph after endotoxemia in vivo in sheep as well as inhibited by 80% the ex vivo production of LTB4 by granulocytes removed from sheep treated 24 h earlier with L-651,392. Although L-651,392 blocked the increase in cyclooxygenase products of arachidonic acid observed in lung lymph after endotoxemia in vivo in sheep, the drug probably did not function directly as a cyclooxygenase inhibitor. L-651,392 did not attenuate the ex vivo production of thromboxane B2 by whole blood from sheep treated 24 h earlier with the drug. L-651,392 attenuated the alterations in pulmonary hemodynamics, lung mechanics, oxygenation, and lung fluid and solute exchange observed after endotoxemia in sheep. We speculate that 5-lipoxygenase products are a major stimulus for cyclooxygenase metabolism of arachidonic acid after endotoxemia in sheep.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2846494     DOI: 10.1152/jappl.1988.65.3.1351

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  5 in total

Review 1.  Pulmonary diseases other than asthma as potential targets for antileukotriene therapy.

Authors:  M Peters-Golden
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

2.  Leukotrienes and ARDS.

Authors:  K L Brigham; J R Sheller
Journal:  Intensive Care Med       Date:  1989       Impact factor: 17.440

3.  L-651,392, a potent leukotriene inhibitor, controls inflammatory process in Escherichia coli pyelonephritis.

Authors:  M Tardif; D Beauchamp; Y Bergeron; C Lessard; P Gourde; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

4.  Adenosine A2 receptor-induced inhibition of leukotriene B4 synthesis in whole blood ex vivo.

Authors:  E Krump; G Lemay; P Borgeat
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

5.  Lipopolysaccharides prime whole human blood and isolated neutrophils for the increased synthesis of 5-lipoxygenase products by enhancing arachidonic acid availability: involvement of the CD14 antigen.

Authors:  M E Surette; R Palmantier; J Gosselin; P Borgeat
Journal:  J Exp Med       Date:  1993-10-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.